Cancer stem cells and somatic stem cells as potential new drug targets, prognosis markers, and therapy efficacy predictors in breast cancer treatment

[thumbnail of Open Access]
Preview
Text (Open Access) - Published Version
· Available under License Creative Commons Attribution.
· Please see our End User Agreement before downloading.
| Preview
Available under license: Creative Commons Attribution
[thumbnail of 21Sep2021biomedicines-1359980_accepted.pdf]
Text - Accepted Version
· Restricted to Repository staff only
Restricted to Repository staff only

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Pershina, O., Ermakova, N., Pakhomova, A., Widera, D. orcid id iconORCID: https://orcid.org/0000-0003-1686-130X, Pan, E., Zhukova, M., Slonimskaya, E., Morozov, S. G., Kubatiev, A., Dygai, A. and Skurikhin, E. G. (2021) Cancer stem cells and somatic stem cells as potential new drug targets, prognosis markers, and therapy efficacy predictors in breast cancer treatment. Biomedicines, 9 (9). 1223. ISSN 2227-9059 doi: 10.3390/biomedicines9091223

Abstract/Summary

New drug targets, markers of disease prognosis, and more efficient treatment options are an unmet clinical need in breast cancer (BC). We have conducted a pilot study including patients with luminal B stage breast cancer IIA-IIIB. Presence and frequency of various populations of cancer stem cells (CSC) and somatic stem cells were assessed in the blood, breast tumor tissue, and normal breast tissue. Our results suggest that patients with BC can be divided into two distinct groups based on the frequency of aldehyde dehydrogenase positive cells (ALDH1+ cells) in the blood (ALDH1hi and ALDH1ow). In the ALDH1hi cells group, the tumor is dominated by epithelial tumor cells CD44+CD24low, CD326+CD44+CD24‒ and CD326‒CD49f+, while in the ALDH1low cells group, CSCs of mesenchymal origin and epithelial tumor cells (CD227+CD44+CD24‒ and CD44+CD24‒CD49f+) are predominant. In vitro CSCs of the ALDH1low cells group expressing CD326 showed high resistance to cytostatics, CD227+ CSCs of the ALDH1hi cells group are sensitive to cytostatics. Epithelial precursors of healthy mammary gland were revealed in normal breast tissue of patients with BC from both groups. The cells were associated with a positive effect of chemotherapy and remission in BC patients. Thus, dynamic control of their presence in blood and assessment of the sensitivity of CSCs to cytostatics in vitro can improve the effectiveness of chemotherapy in BC.

Altmetric Badge

Item Type Article
URI https://reading-clone.eprints-hosting.org/id/eprint/100180
Identification Number/DOI 10.3390/biomedicines9091223
Refereed Yes
Divisions Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
Publisher MDPI
Download/View statistics View download statistics for this item

Downloads

Downloads per month over past year

University Staff: Request a correction | Centaur Editors: Update this record

Search Google Scholar